Buscar
Mostrando ítems 1-10 de 74
Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor
(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2014-10-01)
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular ...
Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon
(Ferrata Storti FoundationPaviaItália, 1998)
Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
(Faculdade de Medicina / USP, 2013)
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2011-12-01)
BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following ...
Identification of driver and subclonal mutations in ASXL1 and IDH1/IDH2 genes in an Argentine series of patients with myelofibrosis
(Wiley Blackwell Publishing, Inc, 2018-08)
Myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm (MPN) characterized by clonal proliferation of hematopoietic stem cells, progressive bone marrow fibrosis, abnormal cytokine expression, anemia, ...
MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis
(Elsevier B.V., 2012-01-01)
To evaluate the grading of fibrosis and immunohistochemical expression of MPL in bone marrow biopsies of ET and PMF. Fibrosis in bone marrow biopsies (BMBs) was evaluated according to the European Consensus for grading of ...
Primary Myelofibrosis: Current Therapeutic Options
(Elsevier Editora Ltda, 2016)